Difference between substrate and inducers in MRR
Reading File
Searching the Web
substrate vs inducers mismatch repair MRR DNA repair
Finding Sources
Finding Sources
The textbook library doesn't have a direct section on substrates vs inducers in MMR. The web results clearly confirm the DNA Mismatch Repair context. Let me provide a thorough, accurate answer.
Substrate vs. Inducers in MMR (DNA Mismatch Repair)
These are two distinct concepts within the MMR pathway:
Substrate (of MMR)
The substrate is the DNA structure that the MMR machinery physically recognizes and acts upon. Specifically:
| Substrate Type | Example | Recognized by |
|---|---|---|
| Base-base mismatches | G:T, A:C, G:G | MutSα (MSH2-MSH6 heterodimer) |
| Small insertion-deletion loops (IDLs) 1-2 nt | 1-nt loop | MutSα (MSH2-MSH6) |
| Larger IDLs (2-13 nt) | 2-13 nt loop | MutSβ (MSH2-MSH3 heterodimer) |
| Hemi-methylated DNA | Newly synthesized strand | Used to distinguish template from new strand (in bacteria) |
- The substrate is the physical DNA molecule - usually a mismatched duplex with one strand nicked (to indicate the "wrong" strand for repair).
- In vitro assays use a hemi-methylated plasmid with a single mismatch as the canonical substrate, where repair results in excision on the unmethylated (newly synthesized) strand.
- Chemotherapy-induced lesions can also become substrates: for example, FdUrd (5-fluorouracil) mispairs are recognized by MutSα as substrates for MMR.
Key point: the substrate is what MMR repairs - it is the input/target molecule.
Inducers of MMR
Inducers are agents or signals that stimulate or upregulate the expression of MMR genes or increase MMR activity. They do not necessarily get repaired themselves - rather, they trigger the pathway.
| Inducer | Mechanism |
|---|---|
| Alkylating agents (e.g., temozolomide, MNNG) | Produce O⁶-methylguanine lesions; MMR recognizes the mismatch but cannot repair it (futile cycling → apoptosis signal) |
| Oxidative stress / ROS | Causes 8-oxoguanine lesions; can be recognized by MMR |
| DNA damaging chemotherapy (cisplatin, 5-FU) | Cisplatin-GG adducts recognized by MutSα; 5-FU creates FdU:A mispairs |
| Replication errors at microsatellites | Increased slippage in repetitive sequences induces MMR activity |
An important nuance: alkylating agents like MNNG are often called MMR "inducers" or "activators" because they cause MMR proteins to engage - but when MMR cannot actually excise the offending lesion (e.g., O⁶-MeG), the pathway cycles futilely and instead triggers apoptotic signaling (via ATM/ATR → CHK1/CHK2 → p53). This is why MMR-deficient tumors are resistant to alkylating agents.
Key Difference Summary
| Substrate | Inducer | |
|---|---|---|
| Definition | The DNA structure MMR recognizes and repairs | Agent/signal that activates or upregulates MMR |
| Role | Input to the repair reaction | Upstream trigger |
| Examples | G:T mismatch, IDL, hemi-methylated DNA, FdU:A pair | Alkylating agents, cisplatin, oxidative stress |
| Fate | Gets excised and replaced by correct nucleotides | May or may not itself be repaired; triggers pathway activity |
| Proteins involved | MutSα/MutSβ bind directly to substrate DNA | Increase transcription/activity of MLH1, MSH2, MSH6, PMS2 etc. |
Clinical Relevance
- Tumors with MMR deficiency (dMMR/MSI-H) cannot process substrates - this leads to microsatellite instability and accumulation of mutations.
- These tumors are also resistant to alkylating inducers (e.g., temozolomide) because the futile cycling/apoptosis signal is absent.
- dMMR is predictive of response to immune checkpoint inhibitors (pembrolizumab is FDA-approved for dMMR solid tumors), because the high mutational burden creates neoantigens.
This is a shared conversation. Sign in to Orris to start your own chat.